SymBiosis Capital Partners, LLC reported 5 positions worth $52.77M for the quarter ended Mar 31, 2026, down 50.1% on the prior quarter. It opened 1 new position, added to 0, trimmed 3 and exited 5. Its largest holding is Evommune, Inc. at 55.8% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| WVE Wave Life Sciences, Inc. | +750.0K | – | $5.44M | 10.3% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| VSTM Verastem, Inc. | -2.00M | -100.0% | $15.44M | Exited |
| AMPG AmpliTech Group, Inc. | -2.56M | -100.0% | $13.23M | Exited |
| PGEN Precigen, Inc. | -3.00M | -100.0% | $12.54M | Exited |
| NUVB Nuvation Bio Inc. | -1.25M | -100.0% | $11.20M | Exited |
| AARD Aardvark Therapeutics, Inc. | -476.6K | -100.0% | $6.26M | Exited |
| RANI Rani Therapeutics Holdings, Inc. | -2.63M | -41.8% | $1.93M | 5.11% |
| CLNN Clene Inc. | -339.4K | -44.0% | $1.67M | 4.03% |
| IVA Inventiva S.A. | -246.0K | -9.5% | $1.37M | 24.76% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| WVE Wave Life Sciences, Inc. | +750.0K | $5.44M | 10.3% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | EVMN Evommune, Inc. | Healthcare | 1.28M | $29.45M | 55.8% | 0 | 0.0% | Unchanged | 3.56% |
| 2 | IVA Inventiva S.A. | Healthcare | 2.35M | $13.06M | 24.76% | -246.0K | -9.5% | Reduced | 1.22% |
| 3 | WVE Wave Life Sciences, Inc. | Healthcare | 750.0K | $5.44M | 10.3% | +750.0K | – | New | 0.37% |
| 4 | RANI Rani Therapeutics Holdings, Inc. | Healthcare | 3.67M | $2.69M | 5.11% | -2.63M | -41.8% | Reduced | 3.67% |
| 5 | CLNN Clene Inc. | Healthcare | 431.1K | $2.13M | 4.03% | -339.4K | -44.0% | Reduced | 3.37% |
Tip. Select a row to see that position’s full history at SymBiosis Capital Partners.
As of its Q1 2026 13F filing, SymBiosis Capital Partners, LLC’s five largest positions were Evommune, Inc. (EVMN) at 55.8%, Inventiva S.A. (IVA) at 24.8%, Wave Life Sciences, Inc. (WVE) at 10.3%, Rani Therapeutics Holdings, Inc. (RANI) at 5.1%, Clene Inc. (CLNN) at 4.0% of the reported portfolio.
SymBiosis Capital Partners, LLC reported a 13F portfolio worth $52.77M across 5 positions for Q1 2026. That is down 50.1% from the previous quarter.
Its largest purchases by value were Wave Life Sciences, Inc. ($5.44M). It opened 1 new positions.
Its largest sales by value were Verastem, Inc. ($15.44M), AmpliTech Group, Inc. ($13.23M), Precigen, Inc. ($12.54M). It exited 5 positions entirely.
From the Form 13F-HR reports SymBiosis Capital Partners, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.